Zacks Investment Research on MSN1d
PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study
Pacira BioSciences PCRX announced that it has dosed the first patient in a mid-stage study of pipeline candidate PCRX-201 ...
Hosted on MSN15d
Pacira Surges 66.8% in Six Months: How Should You Play the Stock?
sciatic nerve block in the popliteal fossa and femoral nerve block in the adductor canal. The Centers for Medicare and Medicaid Services issued a permanent product-specific J-code (J0666 ...
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will ...